PHSI-BRG
PHSI-BRG
Home
Staff
Sarah Al Ashmori
Theophile Bigirumurame
Andy Bryant
Bram Burger
Thomas Chadwick
Svetlana Cherlin
Mike Cole
Holly Fisher
Tony Fouweather
Michael Grayling
Shaun Hiu
Dorcas Kareithi
Ann Breeze Konkoth
Nan Lin
Jingky Lozano-Kuehne
John Matthews
Helen Mossop
Ellen Moss
Jérémie Nsengimana
Luke Ouma
Vicky Ryan
Marzieh Shahmandi
Moha Shojaei
Dawn Teare
James Wason
Faye Williamson
Nina Wilson
Sylvia Zhang
PhD students
Ruqayya Azher
Laura Etfer
Aritra Mukherjee
Pela Okorie
Samuel Sarkodie
Lou Whitehead
Methodology research
Overview
Adaptive designs
Master protocols
Transforming IMID trials
Projects
Publications
News
Courses
Adaptive Designs and Multiple Testing Procedures
Leveraging External Information
Precision Medicine Clinical Trials
Contact
Light
Dark
Automatic
Lozano-Kuehne
[$łess$sup$greater$18$łess$/sup$greater$F]Fluorothymidine(FLT)-PET imaging of thymidine kinase 1 pharmacodynamics in non-small cell lung cancer treated with pemetrexed.
Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
The HERPET study: Imaging HER2 expression in breast cancer with the novel PET tracer [$łess$sup$greater$18$łess$/sup$greater$F]GE-226, a first-in-patient study.
Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer
Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation
[$łess$sup$greater$18$łess$/sup$greater$F] Fluciclatide PET as a biomarker of clinical response to combination therapy of pazopanib and paclitaxel in patients with platinum-resistant or platinum-refractory advanced ovarian cancer: Results of a phase Ib study.
Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study~of~Heart~and Renal Protection (SHARP)
What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
»
Cite
×